Histone deacetylase

Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

Retrieved on: 
Monday, August 2, 2021

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m.

Key Points: 
  • In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m.
  • ET on Monday, August 9, to discuss the Company's financial results and provide a general business update.
  • The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com .
  • Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

Shuttle Pharma Awarded a New Patent for Selective Inhibitors for Cancer Treatment

Retrieved on: 
Thursday, July 29, 2021
Histone deacetylase, HDAC6, Treatment of cancer, Cancer

ROCKVILLE, Md., July 29, 2021 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc (Shuttle Pharma), a Maryland-based developer of new drugs for cancer treatment, was awarded US Patent No.

Key Points: 
  • ROCKVILLE, Md., July 29, 2021 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc (Shuttle Pharma), a Maryland-based developer of new drugs for cancer treatment, was awarded US Patent No.
  • These non-cytotoxic, highly selective inhibitors target the histone deacetylase 6 (HDAC6) enzyme to stimulate the immune system for applications in the treatment of cancers, neurological diseases and immunological disorders.
  • The molecules in this patent enhance Shuttle Pharma's platform technology of selective inhibitor discovery for cancer treatment."
  • Shuttle's HDAC6 selective inhibitors polarize macrophages to an anti-cancer state to stimulate the innate immune response for cancer treatment.

4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T

Retrieved on: 
Tuesday, July 6, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Computer programming, 4th Dimension, Cross-platform software, Software engineering, Protein deacetylase, Software, 4D, Histone deacetylase

4D pharma identified M. massiliensis MRx1299 using its MicroRx platform and previously showed MRx1299 to have specific histone deacetylase (HDAC) inhibitory activity and be a rare prolific producer of pentanoate.

Key Points: 
  • 4D pharma identified M. massiliensis MRx1299 using its MicroRx platform and previously showed MRx1299 to have specific histone deacetylase (HDAC) inhibitory activity and be a rare prolific producer of pentanoate.
  • Using the MicroRx platform we have now shown we have the potential to improve the efficacies of cell therapies such as CAR-T, commented Dr. Imke Mulder, Research Director, 4D pharma.
  • 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
  • 4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut.

Italfarmaco Announces Publication of Positive Long-term Data for Givinostat in Polycythemia Vera Patients in Blood Cancer Journal

Retrieved on: 
Thursday, March 18, 2021
Research, Hospitals, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Orphan drugs, Hematopathology, Drugs, Branches of biology, Clinical medicine, Hydroxamic acids, Givinostat, Antineoplastic drugs, Histone deacetylase, Polycythemia vera, Duchenne, Polycythemia

The results show a long-term benefit in PV patients treated with givinostat, the companys proprietary histone deacetylase (HDAC) inhibitor.

Key Points: 
  • The results show a long-term benefit in PV patients treated with givinostat, the companys proprietary histone deacetylase (HDAC) inhibitor.
  • The publication covers the overall long-term data from patients that were a part of three Phase 1/2 studies, as well as from a compassionate use program.
  • It is being evaluated for safety and efficacy for the treatment of Duchenne- and Becker- Muscular Dystrophy and Polycythemia Vera.
  • Through both marketed drugs and compounds in development, Italfarmaco is dedicated to serving patients whose needs remain largely unmet.

OnKure, Inc. Raises $55 Million Series B Financing

Retrieved on: 
Thursday, March 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Histone deacetylase, Protein deacetylase

OnKure, Inc., a privately-held biopharmaceutical company developing best-in-class, targeted oncology therapeutics, today announced that it has raised $55 million in a Series B financing.

Key Points: 
  • OnKure, Inc., a privately-held biopharmaceutical company developing best-in-class, targeted oncology therapeutics, today announced that it has raised $55 million in a Series B financing.
  • Proceeds will be used to advance the Companys next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
  • The financing was led by Acorn Bioventures with participation from additional new investors Cormorant Asset Management, Surveyor Capital (a Citadel company), Samsara BioCapital, Perceptive Advisors and funds and accounts managed by BlackRock.
  • In connection with the financing, Isaac Manke, Ph.D., Partner at Acorn Bioventures, and Andrew Phillips, Ph.D., Managing Director at Cormorant Asset Management, will join the OnKure board of directors.

The McQuade Center for Strategic Research and Development and Eikonizo Therapeutics Enter Agreement to Develop Treatments for Patients with Rare Diseases

Retrieved on: 
Tuesday, February 9, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Alzheimer's Drug Discovery Foundation, Social finance, HDAC6, Histone deacetylase, Eikonizo Therapeutics, Inc., the McQuade Center for Strategic Research and Development (MSRD), Otsuka

Eikonizo is discovering and developing novel small molecule therapeutics and leveraging companion target engagement technology to de-risk and accelerate development.

Key Points: 
  • Eikonizo is discovering and developing novel small molecule therapeutics and leveraging companion target engagement technology to de-risk and accelerate development.
  • We believe our approach and our brain-penetrant HDAC6 inhibitors could provide a transformative therapy for ALS, said Janice Kranz, Ph.D., co-founder, CEO and president of Eikonizo.
  • Eikonizo and MSRD share values of innovation, scientific rigor and urgency to address unmet medical needs and thus make a meaningful impact on patients lives.
  • Eikonizo is funded by Kevin Kinsella (founder of Avalon Ventures), F-Prime Biomedical Research Initiative (FBRI), Arclight Therapeutics LLC, and Alzheimer's Drug Discovery Foundation (ADDF), among other investors.

Shuttle Pharmaceuticals, Inc. Awarded a New Patent for Dual Function HDAC Molecules for HDAC Inhibition and Ataxia Telangiectasia Mutated Activation for Cancer Treatment

Retrieved on: 
Wednesday, November 4, 2020
Branches of biology, Epigenetics, Biology, Histone deacetylase, Histone acetylation and deacetylation, Chromatin remodeling

These novel compounds enable cancer treatment by the combination of an inhibitory epigenetic mechanism and a stimulatory DNA repair activation process using a single molecule.

Key Points: 
  • These novel compounds enable cancer treatment by the combination of an inhibitory epigenetic mechanism and a stimulatory DNA repair activation process using a single molecule.
  • The patent is the first issued based on Shuttle Pharma's platform technology linking an ATM activating domain to an HDAC inhibitory domain for cancer treatment and protection of normal tissue.
  • Lead inventor Scott Grindrod, PhD describes histone deacetylase (HDAC) inhibitors as a novel class of drugs targeting enzymes involved in regulation of gene expression.
  • HDACs regulate gene expression by changing the conformation of chromatin in cells into a tightly coiled and transcriptionally inactive form.

Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders

Retrieved on: 
Friday, October 23, 2020
Legal, Professional services, Benzimidazoles, Pracinostat, Protein deacetylase, Histone deacetylase

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020.
  • MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.
  • One of MEI Pharma's drug candidates include Pracinostat, an oral histone deacetylase (HDAC) inhibitor.
  • On this news, MEI Pharma's shares fell 18% to close at $3.49 per share and has yet to recover.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, October 1, 2020
Hydroxamic acids, Benzimidazoles, Pracinostat, Drugs, Branches of biology, Antineoplastic drugs, Chemistry, Histone deacetylase, Epigenetics, Orphan drugs, TopoTarget, Romidepsin

Investors have until October 9, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 9, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.
  • MEI Pharmas clinical drug candidates include, among others, Pracinostat, an oral histone deacetylase (HDAC) inhibitor.
  • On July 2, 2020, MEI Pharma issued a press release announcing that it was discontinuing the Phase 3 Pracinostat Trial.

KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development

Retrieved on: 
Thursday, September 24, 2020
Antineoplastic drugs, Kyan, Histone deacetylase inhibitor, Histone deacetylase, Cancer

SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors.KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results.

Key Points: 
  • SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors.KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results.
  • In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate Cancer.The low toxicity and metabolic stability of KYAN-001 indicates a better safety and tolerability profile than FDA approved pan-HDAC inhibitors which suffer from toxicity issues and side effects.KYAN-001 also uniquely inhibits HDAC4 nucleoshuttling to further drive its anti-cancer effects.
  • "We're very excited to proceed with KYAN-001 because of its promising features and we are confident that we can identify optimal combination therapies across multiple cancer indications with Optim.AI," said Lisa Chow, COO and General Counsel of KYAN.
  • KYAN plans to explore at least four cancer indications for KYAN-001 and anticipates advancing KYAN-001 through to Phase I clinical trials by 2022.